DS
PJP icon

David Shaw’s Invesco Pharmaceuticals ETF PJP Stock Holding History

David Shaw’s Portfolio PJP Stock Details PJP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,793
Closed -$224K – 4772
2024
Q1 		$224K Buy
+2,793
New +$216K ﹤0.01% 3881

Other funds holding PJP

PAM
Peak Asset Management Louisville, Colorado $680M AUM 22.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
DBIA
Dumont & Blake Investment Advisors Princeton, New Jersey $445M AUM 31.98% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

David Shaw's PJP Position: Q2 2024 in Review

David Shaw sold out of Invesco Pharmaceuticals ETF (PJP) in Q2 2024, closing a stake of 2,793 shares — an estimated $224K sold.

David Shaw first reported a position in PJP in Q1 2024 and held it in 1 quarter. The position peaked at $224K in Q1 2024. 89 funds tracked by Wall St. Rank hold PJP as of Q2 2024.

  • David Shaw reported no remaining Invesco Pharmaceuticals ETF position as of Q2 2024 after selling out during the quarter.
  • David Shaw sold 2,793 Invesco Pharmaceuticals ETF shares in Q2 2024, an estimated $224K.
  • David Shaw first reported a position in Invesco Pharmaceuticals ETF in Q1 2024 and held it in 1 quarter.
  • David Shaw's Invesco Pharmaceuticals ETF position peaked at $224K in Q1 2024.
  • 89 funds tracked by Wall St. Rank held Invesco Pharmaceuticals ETF as of Q2 2024.

Based on D.E. Shaw & Co's 13F filing for Q2 2024, filed 14 Aug 2024.